<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Loperamide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Loperamide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Loperamide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9571" href="/d/html/9571.html" rel="external">see "Loperamide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11173" href="/d/html/11173.html" rel="external">see "Loperamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F49184879"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Torsades de pointes and sudden death</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of torsades de pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage of loperamide.</p>
<p style="text-indent:0em;">Loperamide is contraindicated in pediatric patients &lt;2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid dosages higher than recommended in adults and pediatric patients ≥2 years due to the risk of serious cardiac adverse reactions.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F189683"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Anti-Diarrheal [OTC];</li>
<li>Diamode [OTC];</li>
<li>FT Anti-Diarrheal [OTC];</li>
<li>Imodium A-D [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1059857"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiarrheal</span></li></ul></div>
<div class="block dop drugH1Div" id="F189704"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a75bf14-d90e-4256-80b3-4ac90f0fc1fe">Diarrhea, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, acute:</b>
<b>Note:</b> Loperamide is not recommended for management of infectious diarrhea in pediatric patients (Devadason 2020; IDSA [Shane 2017]). For patients who are small for chronological age, consider dosing according to weight range and not by age group. Use lowest effective dose for shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:6em;">2 to 5 years weighing 13 to &lt;21 kg: Oral: Initial: 1 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 3 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 8 years weighing 21 to 27 kg: Oral: Initial: 2 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">9 to 11 years weighing 27.1 to 43 kg: Oral: Initial: 2 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 6 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Initial: 4 mg with first loose stool followed by 2 mg/dose after each subsequent loose stool; maximum daily dose: 8 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0557eaae-a6a6-42e9-a777-24db51c1be67">Diarrhea, chronic; secondary to intestinal failure, short-bowel syndrome, or other noninfectious causes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, chronic; secondary to intestinal failure, short-bowel syndrome, or other noninfectious causes:</b> Limited data available; dosing regimens variable: <b>Note:</b> Monitor patients closely for cardiac/respiratory adverse effects and dehydration. Dosage forms without sorbitol or alcohol are preferred in these patients (Ching 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children: Oral: 0.08 to 0.24 mg/kg/day in divided doses every 8 to 12 hours; maximum dose: 2 mg/dose (Buts 1975; Ching 2007). Dosing based on clinical experience and a case series of 10 pediatric patients (age range: 2 to 52 months) (Buts 1975; Ching 2007). In a case series of 6 infants and young children, higher dosing was described: Initial: 1 to 1.5 mg/kg/day in 4 divided doses, with subsequent dose decreased as stool output and diet tolerance improved and patient weight increased. Reported final dose range of 0.25 to 0.5 mg/kg/day in 2 divided doses was used long-term until patient achieved target weight and dietary goals; reported duration of therapy: 6 months to ~2 years (Sandhu 1983).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b02fa284-570d-418c-b04a-787d16cd5b04">Irinotecan-induced diarrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Irinotecan-induced (delayed) diarrhea:</b> Limited data available; consult individual protocols; some organizations have used the following:</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing (Children's Oncology Group 2009; Pediatric Oncology Group of Ontario 2021):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;13 kg: Initial: 0.5 mg after the first loose bowel movement, followed by 0.5 mg every 3 hours while awake; during the night, may administer every 4 hours; maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">13 kg to &lt;20 kg: Initial: 1 mg after the first loose bowel movement, followed by 1 mg every 4 hours; maximum daily dose: 6 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">20 kg to &lt;30 kg: Initial: 2 mg after the first loose bowel movement, followed by 1 mg every 3 hours while awake; during the night, may administer 2 mg every 4 hours; maximum daily dose: 8 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">30 kg to &lt;43 kg: Initial: 2 mg after the first loose bowel movement, followed by 1 mg every 2 hours while awake; during the night, may administer 2 mg every 4 hours; maximum daily dose: 12 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">≥43 kg: Initial: 4 mg after the first loose bowel movement, followed by 2 mg every 4 hours; maximum daily dose: 16 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128477"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥2 years: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> Unlikely to be dialyzed (highly protein bound).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound).</p></div>
<div class="block dohp drugH1Div" id="F51128478"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer labeling. Due to possible effects on first-pass metabolism, use with caution and monitor closely for signs of CNS toxicity.</p></div>
<div class="block doa drugH1Div" id="F189687"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9571" href="/d/html/9571.html" rel="external">see "Loperamide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a75bf14-d90e-4256-80b3-4ac90f0fc1fe">Diarrhea, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, acute (including Travelers' diarrhea):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with known or suspected dysentery (eg, fever ≥38.3°C [101°F] and bloody or mucoid stools), some experts consider use of loperamide with close monitoring as long as antibiotics are also given (ACG [Riddle 2016]; IDSA [Hill 2006]; LaRocque 2022). Although often avoided in patients with <i>Clostridioides</i>
<i>difficile</i> infection, some experts consider use of loperamide with close monitoring as an adjunct to antibiotic therapy if such patients have major fluid losses and no ileus or colonic distention (IDSA/SHEA [McDonald 2018]; Kelly 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 4 mg, followed by 2 mg after each loose stool; maximum: 16 mg/day (OTC: 8 mg/day). Limit use to ≤48 hours (ACG [Riddle 2016]; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa312b57-6861-4fb0-bf9c-29d2da867c2d">Diarrhea, cancer treatment-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, cancer treatment-induced (off-label use): Oral:</b> Initial: 4 mg, followed by 2 mg every 2 to 4 hours or after each loose stool; for diarrhea persisting &gt;24 hours, administer 2 mg every 2 hours (or 4 mg every 4 hours). Continue until 12 hours have passed without a loose bowel movement (Andreyev 2014; Benson 2004; Sharma 2005). <b>Note:</b> Doses &gt;16 mg/day may not provide benefit; consider alternative therapy for diarrhea persisting ≥48 hours (Andreyev 2014; Benson 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neratinib-induced diarrhea, prophylaxis: </i>
<b>Oral:</b> 4 mg 3 times daily (days 1 to 14 of neratinib therapy), followed by 4 mg twice daily (days 15 to 56 of neratinib therapy), followed by 4 mg as needed up to a maximum of 16 mg/day (days 57 to 365 of neratinib therapy) (Nerlynx prescribing information). <b>Note:</b> Antidiarrheal prophylaxis is recommended during the first 56 days of neratinib therapy; initiate with the first neratinib dose. After day 56, titrate dose to achieve 1 to 2 bowel movements/day. Additional antidiarrheal medication may be required for loperamide-refractory diarrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Irinotecan-induced delayed diarrhea:</i>
<b>Oral:</b> 4 mg after first loose stool or first sign of frequent bowel movements, then 2 mg every 2 hours (4 mg every 4 hours at night) until 12 hours have passed without a loose bowel movement (Rothenberg 1996; Sharma 2005).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b245236b-1cd4-4d6d-8a7f-2a20bb444f56">Diarrhea, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 4 mg, followed by 2 mg after each loose stool; maximum: 16 mg/day (manufacturer's labeling). <b>Note: </b>Doses &gt;16 mg/day (eg, up to 40 to 64 mg/day) may be required in some cases (eg, short bowel syndrome). Experience with doses &gt;16 mg/day is generally limited to observational data in specialized centers with close monitoring (DiBaise 2021; Hollington 2004; Mackowski 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dosage:</i> Once diarrhea is controlled, use lowest dosage required to control symptoms; usual maintenance dose: 4 to 8 mg/day as a single dose or in divided doses (eg, 2 mg before meals) (Wald 2021; manufacturer's labeling). If clinical improvement is not observed after ≥10 days of maximally tolerated dosage, symptoms are unlikely to be controlled by further administration. <b>Note: </b>In patients with irritable bowel syndrome with alternating diarrhea and constipation, treatment should be limited to short courses as needed (Wald 2021; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4bdcb597-0d4d-4988-8e91-2f9d768e9929">Enterocutaneous fistula or ileostomy, high-output</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Enterocutaneous fistula (off-label use) or ileostomy (labeled use), high-output:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use of liquid formulations; propylene glycol content may increase output (de Vries 2017; Parli 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Enterocutaneous fistula: </i>
<b>Oral:</b> 4 mg administered 3 to 4 times per day (Parli 2018; Stein 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Ileostomy: </i>
<b>Oral:</b> 2 mg administered 2 to 3 times per day (Landmann 2022; Parli 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment: </b>May increase dose in 2 mg/day increments if fistula output remains elevated (maximum: 16 mg/day) (Parli 2018; manufacturer's labeling). <b>Note: </b>Doses &gt;16 mg/day may be required in refractory cases. Experience with doses &gt;16 mg/day is generally limited to observational data in specialized centers with close monitoring (de Vries 2017; Hollington 2004; Mackowski 2015; Parli 2018).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991639"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988937"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F189659"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (2% to 5%), abdominal cramps (≤3%), nausea (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal discomfort, abdominal distention, abdominal pain, anaphylactic shock, anaphylactoid reaction, angioedema, bullous rash (rare), drowsiness, dyspepsia, erythema multiforme (rare), fatigue, flatulence, hypersensitivity reaction, megacolon, paralytic ileus, pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), toxic megacolon, urinary retention, urticaria, vomiting, xerostomia</p></div>
<div class="block coi drugH1Div" id="F189671"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to loperamide or any component of the formulation; abdominal pain without diarrhea; children &lt;2 years; acute dysentery; acute ulcerative colitis; bacterial enterocolitis (caused by <i>Salmonella</i>, <i>Shigella</i>, and <i>Campylobacter</i>); pseudomembranous colitis associated with broad-spectrum antibiotic use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): When constipation should be avoided; when the inhibition of peristalsis should be avoided</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use if stool is bloody or black.</p></div>
<div class="block war drugH1Div" id="F189656"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic reactions: Rare cases of anaphylaxis and anaphylactic shock have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness or dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Discontinue promptly if constipation, abdominal pain, abdominal distension, blood in stool, or ileus develop. Do not use when peristalsis inhibition should be avoided due to potential for ileus, megacolon and/or toxic megacolon.</p>
<p style="text-indent:-2em;margin-left:4em;">• Torsades de pointes and sudden death: <b>[US Boxed Warning]: Cases of torsades de pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage. Contraindicated in pediatric patients &lt;2 years. Avoid dosages higher than recommended in patients ≥2 years due to the risk of serious cardiac adverse reactions.</b> Cases of syncope and ventricular tachycardia have been reported in adults receiving the recommended dose of loperamide. Cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients &lt;2 years. Avoid use in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of cardiac arrhythmias or other cardiac conditions, elderly, electrolyte abnormalities) and in combination with others drugs known to prolong the QT interval.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• AIDS: Stop therapy at the first sign of abdominal distention; cases of toxic megacolon have occurred in patients with AIDS and infectious colitis (due to viral or bacterial pathogens).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment due to reduced first-pass metabolism; monitor for signs of CNS toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; may be more susceptible to drug-associated effects on the QT interval.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: OTC use is contraindicated in patients &lt;2 years of age due to risks of respiratory depression or cardiac adverse events. Response to loperamide may be variable in pediatric patients due to increased risk of dehydration secondary to diarrhea; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Loperamide is a symptom-directed treatment; if an underlying diagnosis is made, other disease-specific treatment may be indicated. Concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of use: If diarrhea lasts longer than 2 days, symptoms worsen, or abdominal swelling or bulging develops, discontinue use and consult healthcare provider.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self medication (OTC use): Consult health care provider prior to using, if taking antibiotics, if pregnant or breastfeeding, or in the presence of fever, mucus in stool, or a history of liver disease. Serious heart problems may occur if taken more than directed.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878525"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">When managing acute dysentery, concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea; young pediatric patients are particularly susceptible to dehydration and electrolyte imbalances. Antidiarrheal agents are not recommended as part of the management of acute gastroenteritis in infants and children due to risk of serious adverse events (CDC 2003; <i>Red Book</i> [AAP 2021]). A meta-analysis evaluating the use of loperamide for adjunct treatment of acute bacterial gastroenteritis in pediatric patients identified that infants and children who are &lt;3 years of age, malnourished, or moderately to severely dehydrated, or those with bloody diarrhea have a higher risk of serious adverse events (ileus, lethargy, death) even at therapeutic doses (≤0.25 mg/kg/day of loperamide); the potential benefit of loperamide therapy does not outweigh risks; use should be avoided in pediatric patients (IDSA [Shane 2017]; Li 2007). Although data suggest that older children with milder infection and adolescents may see benefit from loperamide therapy, including decreased duration of diarrhea and stool counts, use is not recommended (IDSA [Shane 2017]); if used, patients should be monitored closely for adverse effects or worsening of infection (CDC 2003; Li 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Although OTC use is contraindicated in ages &lt;2 years, loperamide may be necessary in young pediatric patients with intestinal failure or short-bowel syndrome (Buts 1975; Ching 2007; Sandhu 1983). Response to loperamide may be variable in pediatric patients due to increased risk of dehydration secondary to diarrhea; use with caution and monitor for adverse effects.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F189665"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Anti-Diarrheal: 2 mg [contains fd&amp;c blue #1 (brilliant blue), peg-40 hydrog castor oil(cremophor rh40)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imodium A-D: 2 mg [contains fd&amp;c blue #1 (brilliant blue), peg-40 hydrog castor oil(cremophor rh40)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Anti-Diarrheal: 1 mg/7.5 mL (120 mL) [contains fd&amp;c blue #1 (brilliant blue), propylene glycol, quinoline yellow (d&amp;c yellow #10), sodium benzoate; mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imodium A-D: 1 mg/7.5 mL (120 mL, 240 mL) [contains fd&amp;c blue #1 (brilliant blue), propylene glycol, quinoline yellow (d&amp;c yellow #10), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imodium A-D: 1 mg/7.5 mL (120 mL, 240 mL) [contains fd&amp;c blue #1 (brilliant blue), propylene glycol, quinoline yellow (d&amp;c yellow #10), sodium benzoate; mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/7.5 mL (120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anti-Diarrheal: 2 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anti-Diarrheal: 2 mg [DSC] [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anti-Diarrheal: 2 mg [scored; contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anti-Diarrheal: 2 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anti-Diarrheal: 2 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diamode: 2 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Anti-Diarrheal: 2 mg [scored; gluten free; contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imodium A-D: 2 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imodium A-D: 2 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg</p></div>
<div class="block geq drugH1Div" id="F189652"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F189673"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Imodium A-D Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Loperamide HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.13 - $1.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Imodium A-D Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/7.5 mL (per mL): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Loperamide HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/7.5 mL (per mL): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Imodium A-D Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Loperamide HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.07 - $0.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613175"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Drink plenty of fluids to help prevent dehydration.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Shake well before administering dose.</p></div>
<div class="block adm drugH1Div" id="F49184881"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with plenty of clear fluids to prevent dehydration.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Shake well before administering dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Cancer treatment-induced diarrhea: Consider administering 30 minutes prior to eating 4 times daily to slow gastrocolic reflex (Andreyev 2014).</p></div>
<div class="block sts drugH1Div" id="F2127376"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 20°C and 25°C (68°F and 77°F).</p></div>
<div class="block usep drugH1Div" id="F53567575"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Prescription products: Treatment of acute nonspecific diarrhea (FDA approved in ages ≥2 years and adults); treatment of chronic diarrhea associated with inflammatory bowel disease and reduction of ileostomy discharge volume (FDA approved in adults); has also been used for chronic diarrhea due to multiple causes, including short-bowel syndrome, organic lesions, idiopathic (functional diarrhea), and late-onset irinotecan-induced.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC products: Control symptoms of diarrhea, including traveler's diarrhea (FDA approved in ages ≥6 years and adults).</p></div>
<div class="block mst drugH1Div" id="F189734"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Imodium A-D may be confused with Indocin</p>
<p style="text-indent:-2em;margin-left:4em;">Loperamide may be confused with furosemide, Lomotil</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Loperamide, when used in pediatric patients &lt;2 years of age with acute infectious diarrhea, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of ileus and lethargy (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Indiaral [France] may be confused with Inderal and Inderal LA brand names for propranolol [US, Canada, and multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Lomotil: Brand name for loperamide [Mexico, Philippines], but also the brand name for diphenoxylate [US, Canada, and multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Lomotil [Mexico, Philippines] may be confused with Ludiomil brand name for maprotiline [multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2127373"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F189661"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Loperamide may enhance the adverse/toxic effect of Alvimopan. Specifically, alvimopan gastrointestinal adverse effects may be increased. Loperamide may diminish the therapeutic effect of Alvimopan.  Management: Consider avoiding coadministration of alvimopan and loperamide due to the risk of gastrointestinal adverse effects and pharmacologic antagonism.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Loperamide-Loperamide Oxide may increase the serum concentration of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Loperamide-Loperamide Oxide may enhance the constipating effect of Eluxadoline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of Loperamide-Loperamide Oxide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: May increase the serum concentration of Loperamide. Management: When first using loperamide with lonafarnib, do not exceed a loperamide dose of 1 mg/day. If needed, the loperamide dose can then be slowly and cautiously increased according to the loperamide labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May enhance the CNS depressant effect of Loperamide-Loperamide Oxide. Loperamide-Loperamide Oxide may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Loperamide-Loperamide Oxide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May enhance the QTc-prolonging effect of Loperamide-Loperamide Oxide. QuiNINE may increase the serum concentration of Loperamide-Loperamide Oxide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Loperamide-Loperamide Oxide may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F1623722"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F2127372"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse effects have not been observed in animal reproduction studies. Information related to loperamide use in pregnancy is limited and data are conflicting (Einarson 2000; Källén 2008). For acute diarrhea in pregnant women, some clinicians recommend oral rehydration and dietary changes; loperamide in small amounts may be used only if symptoms are disabling (Wald 2003).</p></div>
<div class="block mopp drugH1Div" id="F53567550"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Stool output, CNS toxicity assessment, respiratory and cardiac status (particularly in very young pediatric patients).</p></div>
<div class="block pha drugH1Div" id="F189655"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acts directly on circular and longitudinal intestinal muscles, through the opioid receptor, to inhibit peristalsis and prolong transit time; reduces fecal volume, increases viscosity, and diminishes fluid and electrolyte loss; demonstrates antisecretory activity. Loperamide increases tone on the anal sphincter</p></div>
<div class="block phk drugH1Div" id="F189670"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Poor.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Poor penetration into brain.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via oxidative N-demethylation; CYP2C8 and CYP3A4 (major) and CYP2B6 and CYP2D6 (minor) role in N-demethylation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 9.1 to 14.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Liquid: 2.5 hours; Capsule: ~5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F189674"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lomidex | Lopodium</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Colifilm | Contem | Custey | Dotalsec | Elcoman | Espaven sec | Excelentia antidiarreico | Fada loperamida | Ionet | Lanseka | Lefa Enteril L | Loperamida | Loperamida cevallos | Loperamida fabra | Loperamida ilab | Loperamida vannier | Loperix | Lovopren | Minicam | Nodiar | Normasec | Plexol | Plorinoc | Regulane | Regulane cb | Suprasec | Viltar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Enterobene | Imodium | Imosec | Loperamid | Loperamid sandoz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal Anti Diarrh | Apohealth diarrhoea relief | Blooms the chemist diarrhoea relief | Chemists own diarrhoea relief | Cm diarrhoea rlf | Diarrhoea Relief | Gastrex | Gastro lieve | Gastrostop | Harmonise | Imodium | Lopedium | Lorrex | O/n diarrhoea rel | Pharmacy care anti diarrhoea | Soul pattinson diarrhoea | Tw diarrhoea rlf</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Dirocap | Dirolin | Imotil | Lomid | Lomosec | Lopamid | Lopan | Loper | Loperin | Loperodium | Nomotil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ercestop | Imodium | Imodium aktuapharma | Loperamide Eurogenerics | Loperamide merck-generics | Loperamide Mylan | Loperamide Ratiopharm | Loperamide sandoz | Loperamide teva generics belgium | Toriac</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Diarloc | Loperamide</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Diarostad | Imodium | Imomed | Lopedium | Loperamid | Vacontil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de loperamida | Closecs | Diafuran | Diarresec | Diasec | Disteran | Enterocler | Enterosec | Imosec | Intestin | Kaosec | Loperamida | Loperin | Magnostase | Obstar</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Amavita loperamid | Binaldan nouvelle formule | Imodium | Loperamid | Loperamid HelvePharm | Loperamid sandoz | Loperamid spirig hc | Loperamid streuli | Loperamid zentiva | Loperamid-mepha | Sun store loperamid</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Adco loperamide | Creatimo | Diarloc | Diarum | Loperamide denk | Loperium</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Capent | Coliper | Lopediar | Loperamida | Salvacoll | Sikim</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fu xie ding | Imodium | Loperamide | Lopermide | Yi meng ting</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Adbriotico | Diarmicin | Imodium | Loperamida | Loperamida clorhidrato | Loperamida MK | Novadiar | Pangetan nf | Plenterox | Sindiar | Stomalix</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lopacut | Loperamid dr.max | Loperamide aurovitas | Loperon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Azuperamid | Boxolip | D-stop | Duralopid | Endialop | Endiaron l | Imodium | Imodium akut | Imodium n | Lop | Lop dia | Lopa hemopharm | Lopacut | Lopalind | Lopedium | Lopepham | Lopera | Loperamerck | Loperamid | Loperamid AbZ akut | Loperamid akut | Loperamid al | Loperamid Aristo | Loperamid axicur | Loperamid Elac | Loperamid puren | Loperamid sandoz | Loperamide heumann | Loperhoe | Loperhoe akut | Lopetrans | Sanifug</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Imolope</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alka ad | Diarrexanol | Imodium | Lopefar | Lopemida | Loperamida | Loperamida Denk | Loperil | Lopirin | Peristal | Prodom</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lopediar | Loperamida MK | Loperamide | Loridin | Novalop | Velaral</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lopacut | Lopedium | Lopedium express | Loperamid | Loperamidum-ratiopharm | Vacontil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Loperasin | Lopodium | Motijust | Sedomid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Diarfin | Elissan | Fortasec | Imodium | Imosec | Loperamida belmac | Loperamida inkey | Loperamida rimafar | Loperan | Loperkey | Taguinol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Vacontil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Imocur | Imodium | Imodium orion | Lopacut | Lopex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Altocel | Antidiar | Delalande diarrhee | Diaretyl cooper | Dysentec | Dyspagon | Ercestop | Gastrowell Loperamide | Imodium | Imodiumliquicaps | Imossel | Indiaral | Lodiarid | Lopelin | Loperamide | Loperamide Almus | Loperamide arrow | Loperamide biogaran | Loperamide cristers | Loperamide evolugen | Loperamide g gam | Loperamide gifrer | Loperamide gnr | Loperamide hexal | Loperamide ivax | Loperamide Lyoc | Loperamide merck | Loperamide Phr | Loperamide Qualimed | Loperamide Ratiopharm | Loperamide ratiopharm conseil | Loperamide rpg | Loperamide sandoz | Loperamide teva | Loperamide zydus | Loperium | Nabutil | Nimaz | Peracel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arret | Diafix | Diah limit | Diaquitte | Diareze | Diarid | Diarrhoea Relief | Diasorb | Diocalm | Diocalm ultra | Diocaps | Dioraleze | Entrocalm | Imodium | Imodium IBS Relief | Imodium jan | Lodiar | Loperagen | Loperamide | Loperamide Almus | Loperamide cox | Loperamide Galpharm | Loperamide kent | Loperamide sandoz | Loritax | Norimode | Normaloe</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Eskamide</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Neo enteroseptol | Neo-Septol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">APO Loperamide | Bf-Loperamide | Colodium | Diacalm | Diacure | Diastop | Diatabs Reformulated | Eurodium | Imocon | Imodium | Imotol | Karenamide | Liderium | Lopa | Lopaine | Loper | Lopera | Loperamide | Loperamil | Loperax | Loperin | Loperium | Lopermide | Miraton | Nt diorea | Pera | Qualiper | Reximide | Sanpo | Synodium | Tedium | Undiarrhea | Uni-Motil | Vacontil | Vidaperamide</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lordiar | Seldiar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Enterobene | Huma-loperamide | Imodium | Lopacut | Lopedium | Loperacap</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alphamid | Amerol | Antidia | Bidium | Colidium | Diadium | Diaramid | Diasec | Diastrix | Gradilex | Imodan | Imodium | Imomed | Imore | Imosa | Inamid | Lexadium | Licodium | Lodia | Lomodium | Lopamid | Loperamide | Loperil | Loremid | Mecodiar | Midix | Motilex | Normotil | Normudal | Opox | Oramide | Primodiar | Primodium | Renamid | Rhomuz | Tanitril | Tracodia | Xepare | Zeroform</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Arret | Boots diarrhoea relief | Imodium</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Loperid | Loperium | Rekamid | Rekamide | Shilshul X | Stopit</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Allexit | Alstop | Andial | Diarlop | Diarsec | El par | Eldoper | Imodium | Lomide | Lomin | Lopamide | Loparet | Loperam | Loperamide | Loperamide HCL | Lopipen | Lopox | Lopramide | Loramyl | Lupidium | Peeceeo | Ridol | Rokamide | Roko | Sestil ad | Starlop | Tropamide</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">As entros top | Diarastop | Loperamide awa | Loprasaf | Lopratil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Clarimide Diarrea | Diarstene | Diarstop | Dissenten | Dissenten antidiarrea | Imodium | Lopemid | Loperamide | Loperamide aurobindo | Loperamide doc</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Imotril | Loperium | Razentil | Vacontil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Beltessa | Beltessa chemiphar | Cagudalin | Clalet | Fululondo | Fussen | Kaizac | Lonbanin | Lopecald | Lopemic | Lopemin | Lopena | Loperamide emec | Loperamide HCL | Loperan | Loperanil | Loseramin | Lospolia | Marupi geridome | Miropin | Rospolia | Signal geridome | Sparamid | Taipemin | Trot</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adco loperamide | Astodium | Dialin | Diarril | Dissenten | Eldoper | Immobulk | Immolab | Imodium | Imotil | Lomide | Lopedium | Loperamide | Lopeshal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daeil loperamide | Daewha loperamide hcl | Gl loperamide hcl | Lamid | Lopaine | Lopamide | Lopamin | Lopera | Loperamide | Loperamide HCL | Loperi | Loperin | Lopestop | Lopidine | Lopirem | Lopmin | Lopo | Maped | Noberan | Noparon | Peramine | Rheofen | Samnam loperamide</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lopodium</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Imorivo | Loperamide | Loperamide arrow | Loperium</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Diarrheel | Imodium | Imodium Original | Lopacut | Lopedium | Lopedium express | Lopedium t | Loperamid | Loperamidum wzf polfa</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dyspagon | Ercestop | Imodium | Lopedium | Loperamid | Loperamide Eurogenerics</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lopacut | Lopedium | Lopedium express | Loperamid | Roko</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Loperium | Stadiar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acanol | Acqta | Apopera | Degortkap | Deroser | Diaperol | Dilostop | Dipera | Exclefin | Hurplex | Imodium | Lomotil | Lop | Loperamida | Loperamida gi serr | Loperamida landsteiner | Lorabest | Nodiamex | Pramidal | Raxamida | Rediarin | Tac Alto | Tarmin | Valfam | Wayper</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anpromide | Beamodium | Colodium | Diatrol | Imocap | Imodium | Imotab | Lomide | Lomodium | Loperamide | Loperax | Loperium | Lopermide | Lopex | Loramide | Modim | Primodium | Reximide | Vacontil</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Alapharm loperamide | Amakin loperamide | Diaflush | Diamotil | Diaoff | Diareasec | Diarrex | Dondiam | Lodium | Lokel's loperamide | Loperamide | Loperamide bp | Olidiacure | P one loperamide | Palomide | Phinodiom | Rgi loperamide | Sunymet loperamide | Swiperamide | Talibex loperamide | Teka loperamide | Tivapramide | Zimotil | Zukcure</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diacure | Diarem | Diarree remmer | Diarreeremmende | Diarreeremmer htp loperamide hcl | Diarreeremmer loperamide hcl | Diarreeremmer Loperamide Hcl Ham | Idyl diarreeremmer loperamide hcl | Imodium | Jumbo diarreeremmer loperamide hcl | Livsane diarreeremmer loperamide hcl | Loperamide | Loperamide HCL | Loperamide hcl flx | Loperamide HCl Kring | Loperamide Hcl Merck | Loperamide Hcl PCH | Loperamide Hcl Sandoz | Rxt loperamide hcl | San loperamide hcl</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Imodium a-d | Imodium n | Imolopera | Lopacut | Loperamid | Loperamid norfri | Salvacolina | Travello</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">APO Loperamide | Diafix | Diamide | Dicap | Gastro-stop | Imodium | Nodia | Pharmacy health diarrhoea relief</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Antidiarr | Desitin | Donafan | Donalab | Donamed F | Donapharm | Imodium | Lofer | Lopediar | Loperam | Loperamida | Loperamida clorhidrato | Lusafan f | Peripharm | Pevitrel | Tap forte | Tobafan forte | Toban | Toban f</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Byerrhea | Chrisolop | Diamide | Diarhemide | Diarin | Diasten | Diaster | Diastop | Diatabs | Dli-loperamide hydrochloride | Harvimide | Imodium | Lbx | Lodarest | Lomotil | Loniper | Lopen | Loperamide | Loperamide Pacif | Lopran | Lopromin | Lorban | Lormide | Rodderhea | Stoform | Tgp loper | Tymedon | Vexil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adromide | Coliper | Diastop | Dilop | Emod | Floramex | Glodium | Hoff | Imodium | Jamide | Lomide | Lopamide | Lopedium | Lopemid | Loperam | Loperamid | Lopium | Lopramex | Lopran | Stodium | Tabromide</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aurostop | Dissenten | Imodium | Laremid | Lopacut | Loper | Loperamid | Loperamid apteo med | Loperamid Dr. Max | Loperamide aurovitas | Stoperan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Anti Diarrheal | Diamode | Imodium | Imodium a-d | Imodium ad | Imogen | Loperamide HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Diastrolib | Imodium | Loperamida | Loperamida generis | Lopitum | Loride</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Contem | Diaxin nf | Imodium | Loremid | Teramotil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Imodium Instant</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Enteramid | Enterium | Imodium | Lopedium | Lopegen | Lopemidol | Loperamid | Loperamid aurobindo | Loperamid bioeel | Loperamid dr.max | Loperamid laropharm | Loprid | Tammex akut</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Diara | Enterobene | Imodium | Lopedium | Loperamid | Loperamide | Loperamide akrikhin | Loperamide grindex | Loperamide stada | Loperamide velpharm | Neo enteroseptol | Superilop | Vero loperamid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lopodium | Pms-loperamide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dimor | Imodium | Imolopera | Lopacut | Loperamid abece | Loperamid apofri | Loperamid brown | Loperamid evolan | Loperamid medical valley | Loperamid Merck NM | Loperamid Mylan | Travello</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Amerol | Colodium | Diatabs | Diatrol | Eldoper | Imodium | Loperamide | Loperamil | Loperax | Loramide | Lorpa | Vacontil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lopacut | Seldiar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Belopera | Imodium | Lopacut | Loperamid | Loperamid dr.max | Tammex akut</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Diarreashif | Weldiarrhoel</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bismadium | Bismatril | Dainox | Daiven | Diamide | Dianox | Diara | Diarent | Diarine | Diarodil | Diretrol | Diven | Entermid | Ginzadium | Hawkpermide | Himlomide | Immotab | Imodine | Imodium | Imonox | Impelium | Impore | Leomide | Limadryl | Limatril | Lodil | Lomedil | Lomide | Lopedium | Lopela | Loperamide | Loperan | Lopercin | Loperdium | Loperia | Loperil | Lopermide | Lopil | Loramide | Lorapil | Manodium | Mantril | Mecodium | Medium | Miderlar | Modim | Monamide | Nopidium | Noxzy | Operium | Patardium | Peodium | Perasian | Permid | Phihadium | Profura | Pybutil | Remytil | Ropa | Sbob | Setonox | Sumedium | Tedium | Vacontil</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diaretyl | Idium | Imodium | Indiaral | Sediaryl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Diadef | Imodium | Lopermid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">An Lih | Antidia | Cenloper | Emodine | Emose | Fulnin | Geline | Genlatin | Gerium | Hocular | Imocon | Imode | Imodine | Imodium | Imodium a-d | Imolex | Imoli | Imomide | Imora | Imosen | Iridine | Isidium | Julilin | Ker Li | Kuzomea | Lecotin | Liaid | Licolin | Liderium | Limodium | Lipitin | Liys | Loidium | Lolilin | Lopedin | Lopedium | Lopela | Lopemic | Loper | Lopera | Loperadin | Loperadium | Loperam | Loperamide | Loperamin | Loperdin | Loperin | Loperium | Lopetin | Moledium | Mori | Peramide | Ridan | Safe | Sanpo | Ufunin | Undiarrhea | Winlipan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lopedium | Loperamid | Loperamid Kmp | Loperamid Rivopharm</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Astodium | Dialin | Imodium | Kamodium | Loperaren</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Corol | Fadal | Imodium | Loper | Loperamida | Loperamida athena | Pramidef</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antilax | Glucitol | Imodium | Loperam | Loperamida | Loperamida cevallos</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Imoboston | Lopetab | Parepemic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco loperamide | Betaperamide | Cipla loperamide | Gastron | Imodium | Lenide-t | Norimode | Prodium | Rolab-loperamide</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ar pramide | Colodium | Imodium | Lomodium | Lopamet | Lopamide | Loperamide denk | Loprade | Motionil | Roko</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Imodium | Lockit</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-8120919">
<a name="8120919"></a>Abigerges D, Armand JP, Chabot GG, et al, “Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea,” <i>J Natl Cancer Inst</i>, 1994, 86(6):446-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/8120919/pubmed" id="8120919" target="_blank">8120919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25186048">
<a name="25186048"></a>Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. <i>Lancet Oncol</i>. 2014;15(10):e447-e460. doi: 10.1016/S1470-2045(14)70006-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/25186048/pubmed" id="25186048" target="_blank">25186048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15254061">
<a name="15254061"></a>Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. <i>J Clin Oncol</i>. 2004;22(14):2918-2926.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/15254061/pubmed" id="15254061" target="_blank">15254061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1174894">
<a name="1174894"></a>Buts JP, Petit BF, and de Meyer R, "Letter: Loperamide in Treatment of Persistent Diarrhoea in Children," <i>Br Med J</i>, 1975, 3(5986):766-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/1174894/pubmed" id="1174894" target="_blank">1174894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14627948">
<a name="14627948"></a>Centers for Disease Control and Prevention, "Managing Acute Gastroenteritis Among Children: Oral Rehydration, Maintenance, and Nutritional Therapy," <i>MMWR Recomm Rep</i>, 2003, 52(RR-16):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/14627948/pubmed" id="14627948" target="_blank">14627948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention. Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Updated June 13, 2017. Accessed September 6, 2017.</div>
</li>
<li>
<div class="reference">
                  Children's Oncology Group. Supportive care guidelines. https://childrensoncologygroup.org/docs/default-source/pdf/supportive-care-guidelines_archived_10-7-09_diarrhea_august2018.pdf?sfvrsn=65effebd_2. Updated 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042954">
<a name="18042954"></a>Ching YA, Gura K, Modi B, Jaksic T. Pediatric intestinal failure: nutrition, pharmacologic, and surgical approaches. <i>Nutr Clin Pract</i>. 2007;22(6):653-663. doi:10.1177/0115426507022006653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/18042954/pubmed" id="18042954" target="_blank">18042954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20087095">
<a name="20087095"></a>Datta V, Engledow A, Chan S, Forbes A, Cohen CR, Windsor A. The management of enterocutaneous fistula in a regional unit in the United Kingdom: a prospective study. <i>Dis Colon Rectum</i>. 2010;53(2):192-199. doi:10.1007/DCR.0b013e3181b4c34a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/20087095/pubmed" id="20087095" target="_blank">20087095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Devadason.1">
<a name="Devadason.1"></a>Devadason D, Goldman DA. Management of diarrhea. In: Wyllie R, Hyams JS, Kay M, eds. <i>Pediatric Gastrointestinal and Liver Disease</i>. 6th ed. Elsevier; 2020:chap 90.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28613003">
<a name="28613003"></a>de Vries FEE, Reeskamp LF, van Ruler O, et al. Systematic review: pharmacotherapy for high-output enterostomies or enteral fistulas. <i>Aliment Pharmacol Ther</i>. 2017;46(3):266-273. doi:10.1111/apt.14136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/28613003/pubmed" id="28613003" target="_blank">28613003</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  DiBaise J. Management of the short bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10758415">
<a name="10758415"></a>Einarson A, Mastroiacovo P, Arnon J, et al, "Prospective, Controlled, Multicentre Study of Loperamide in Pregnancy," <i>Can J Gastroenterol</i>, 2000, 14(3):185-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/10758415/pubmed" id="10758415" target="_blank">10758415</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ericsson CD, "Nonantimicrobial Agents in the Prevention and Treatment of Traveler's Diarrhea," <i>Clin Infect Dis</i>, 2005, 41(Suppl 8):557-63.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2192552">
<a name="2192552"></a>Ericsson CD and Johnson PC, “Safety and Efficacy of Loperamide,” <i>Am J Med</i>, 1990, 88(6A):10S-14S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/2192552/pubmed" id="2192552" target="_blank">2192552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17109284">
<a name="17109284"></a>Hill DR, Ericsson CD, Pearson RD, et al; Infectious Diseases Society of America. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(12):1499-1539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/17109284/pubmed" id="17109284" target="_blank">17109284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15505866">
<a name="15505866"></a>Hollington P, Mawdsley J, Lim W, Gabe SM, Forbes A, Windsor AJ. An 11-year experience of enterocutaneous fistula. <i>Br J Surg</i>. 2004;91(12):1646-1651. doi:10.1002/bjs.4788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/15505866/pubmed" id="15505866" target="_blank">15505866</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Imodium [product monograph]. Markham, Ontario, Canada: McNeil Consumer Healthcare; December 2016.</div>
</li>
<li>
<div class="reference">
                  Imodium A-D (loperamide) caplets [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; received March 2019.</div>
</li>
<li>
<div class="reference">
                  Imodium A-D (loperamide) caplets [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; September 2021.</div>
</li>
<li>
<div class="reference">
                  Imodium A-D (loperamide) liquid-filled capsules [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ImodiumA-D.4">
<a name="ImodiumA-D.4"></a>Imodium A-D (loperamide) oral solution [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; received April 2023.</div>
</li>
<li>
<div class="reference">
                  Imodium A-D (loperamide) oral solution [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; March 2022.</div>
</li>
<li>
<div class="reference">
                  Imodium A-D (loperamide) tablets [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; received April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18394096">
<a name="18394096"></a>Källén B, Nilsson E, and Otterblad Olausson P, "Maternal Use of Loperamide in Early Pregnancy and Delivery Outcome," <i>Acta Paediatr</i>, 2008, 97(5):541-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/18394096/pubmed" id="18394096" target="_blank">18394096</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kelly CP, Lamont T, Bakken JS. Clostridioides (formerly Clostridium) difficile infection in adults: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10699539">
<a name="10699539"></a>Kornblau S, Benson AB, Catalano R, et al, “Management of Cancer Treatment-Related Diarrhea. Issues and Therapeutic Strategies,” <i>J Pain Symptom Manage</i>, 2000, 19(2):118-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/10699539/pubmed" id="10699539" target="_blank">10699539</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Landmann RG, Cashman AL. Ileostomy or colostomy care and complications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference">
                  LaRocque R, Harris JB. Travelers' diarrhea: Treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17388664">
<a name="17388664"></a>Li ST, Grossman DC, and Cummings P, "Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-analysis," <i>PLoS Med</i>, 2007, 4(3):e98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/17388664/pubmed" id="17388664" target="_blank">17388664</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Loperamide hydrochloride [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; October 2016.</div>
</li>
<li>
<div class="reference">
                  Loperamide hydrochloride [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; March 2022.</div>
</li>
<li>
<div class="reference">
                  Loperamide hydrochloride [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals LLC; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25903209">
<a name="25903209"></a>Mackowski A, Chen HK, Levitt M. Successful management of chronic high-output ileostomy with high dose loperamide. <i>BMJ Case Rep</i>. 2015;2015:bcr2015209411. doi:10.1136/bcr-2015-209411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/25903209/pubmed" id="25903209" target="_blank">25903209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morturano.2012">
<a name="Morturano.2012"></a>Morturano R. Management of chemotherapy-induced diarrhea. OncoLink. https://www.oncolink.org/healthcare-professionals/o-pro-portal/articles-about-cancer-treatment-and-medications/management-of-chemotherapy-induced-diarrhea. Updated October 2012. Accessed April 7, 2017.</div>
</li>
<li>
<div class="reference">
                  Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1623917">
<a name="1623917"></a>Nikodem VC and Hofmeyr GJ, "Secretion of the Antidiarrhoeal Agent Loperamide Oxide in Breast Milk," <i>Eur J Clin Pharmacol</i>, 1992, 42(6):695-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/1623917/pubmed" id="1623917" target="_blank">1623917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27406346">
<a name="27406346"></a>Park JW, Liu MC, Yee D, et al; I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. <i>N Engl J Med</i>. 2016;375(1):11-22. doi: 10.1056/NEJMoa1513750.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/27406346/pubmed" id="27406346" target="_blank">27406346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29448989">
<a name="29448989"></a>Parli SE, Pfeifer C, Oyler DR, Magnuson B, Procter LD. Redefining "bowel regimen": pharmacologic strategies and nutritional considerations in the management of small bowel fistulas. <i>Am J Surg</i>. 2018;216(2):351-358. doi:10.1016/j.amjsurg.2018.01.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/29448989/pubmed" id="29448989" target="_blank">29448989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-POGO.1">
<a name="POGO.1"></a>Pediatric Oncology Group of Ontario (POGO). 3.7.2 Provider guide: prevention and management of irinotecan-induced diarrhea. https://www.pogo.ca/wp-content/uploads/2022/01/3.7.2-Provider-Guide-%E2%80%93-Prevention-and-Management-of-Irinotecan-Induced-Diarrhea.pdf. Updated December 15, 2021. Accessed April 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27068718">
<a name="27068718"></a>Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol.</i> 2016;111(5):602-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/27068718/pubmed" id="27068718" target="_blank">27068718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8648367">
<a name="8648367"></a>Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. <i>J Clin Oncol</i>. 1996;14(4):1128-1135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/8648367/pubmed" id="8648367" target="_blank">8648367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6830273">
<a name="6830273"></a>Sandhu BK, Tripp JH, Milla PJ, et al, "Loperamide in Severe Protracted Diarrhoea," <i>Arch Dis Child</i>, 1983, 58(1):39-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/6830273/pubmed" id="6830273" target="_blank">6830273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15683818">
<a name="15683818"></a>Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. <i>Lancet Oncol</i>. 2005;6(2):93-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/15683818/pubmed" id="15683818" target="_blank">15683818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Stein SL. Enterocutaneous and enteroatmospheric fistulas. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28057664">
<a name="28057664"></a>Swain SM, Schneeweiss A, Gianni L, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. <i>Ann Oncol</i>. 2017;28(4):761-768. doi: 10.1093/annonc/mdw695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/28057664/pubmed" id="28057664" target="_blank">28057664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635420">
<a name="12635420"></a>Wald A, "Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy," <i>Gastroenterol Clin North Am</i>, 2003, 32(1):309-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/12635420/pubmed" id="12635420" target="_blank">12635420</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 4, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12561 Version 586.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
